Immuneering Corp
IMRX · XNASCIK 1790340fmd_1DCFF2TQW9HFCWF323G75BM3FXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (59)
- Net income
- (56)
- Free cash flow
- (45)
Latest quarter · Q3 FY2026
Millions- Operating income
- (26)
- Net income
- (24)
- Free cash flow
- (17)
Daily close · IMRXIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions3.79 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Immuneering Corp (IMRX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$59.4 million | -$64.1 million | 10-K 2026-03-06 · proof | |
| Net income | -$56 million | -$61 million | 10-K 2026-03-06 · proof | |
| Cash from operating activities | -$45.3 million | -$55 million | 10-K 2026-03-06 · proof | |
| Free cash flow | -$45.5 million | -$55.1 million | 10-K 2026-03-06 · proof | |
| Total assets | $232 million | $52.7 million | +340.1% | 10-K 2026-03-06 · proof |
| Total liabilities | $13.5 million | $11.3 million | +19.2% | 10-K 2026-03-06 · proof |
| Cash and cash equivalents | $128.6 million | $36.1 million | +255.9% | 10-K 2026-03-06 · proof |
- What was Immuneering Corp (IMRX)'s operating income in fiscal 2025?
- Immuneering Corp (IMRX) reported operating income of -$59.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$64.1 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2026. SEC
- What was Immuneering Corp (IMRX)'s net income in fiscal 2025?
- Immuneering Corp (IMRX) reported net income of -$56 million for fiscal 2025 (the year ended Dec 31, 2025), against -$61 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2026. SEC
- What was Immuneering Corp (IMRX)'s cash from operating activities in fiscal 2025?
- Immuneering Corp (IMRX) reported cash from operating activities of -$45.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$55 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2026. SEC
- What was Immuneering Corp (IMRX)'s free cash flow in fiscal 2025?
- Immuneering Corp (IMRX) reported free cash flow of -$45.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$55.1 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2026. SEC
- What are Immuneering Corp (IMRX)'s total assets?
- As of Dec 31, 2025, Immuneering Corp (IMRX) reported total assets of $232 million, against $52.7 million a year earlier (+340.1%). Source: the 10-K filed with the SEC on Mar 6, 2026. SEC
- What are Immuneering Corp (IMRX)'s total liabilities?
- As of Dec 31, 2025, Immuneering Corp (IMRX) reported total liabilities of $13.5 million, against $11.3 million a year earlier (+19.2%). Source: the 10-K filed with the SEC on Mar 6, 2026. SEC
- What are Immuneering Corp (IMRX)'s cash and cash equivalents?
- As of Dec 31, 2025, Immuneering Corp (IMRX) reported cash and cash equivalents of $128.6 million, against $36.1 million a year earlier (+255.9%). Source: the 10-K filed with the SEC on Mar 6, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:IMRX&period_type=annual&limit=5"Information only, not investment advice.